Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Qi Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8776-8730, 0000-0002-7724-1289; OpenAlex author ID A5100350268. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 trial · 2025: none · 2026: 5 papers

Papers 7

  1. Tumor Microenvironment-Responsive Nanoreactor Induces Disulfidptosis in Pancreatic Cancer via Metabolic Interference and Redox Catalysis. First author DOI 10.1002/advs.76146↗
  2. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  3. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  4. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Co-author DOI 10.1155/mi/2632235↗
  5. Breaking barriers: nano-boosted drug delivery systems in overcoming the defenses of pancreatic cancer. Co-author DOI 10.1186/s12943-026-02712-8↗
  6. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Co-author DOI 10.1136/gutjnl-2020-322744↗
  7. Analysis of clinical syndromes in 47 patients with pancreatic cancer at late stage. Co-author DOI 10.1016/s0254-6272(11)60037-x↗

Trials 1

  1. TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor Principal investigator NCT06619886↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rainer Christoph Miksch · 1 shared paper, 2026 · strength 0.29
  2. Bernhard Willibald Renz · 1 shared paper, 2026 · strength 0.29
  3. Matthias Ilmer · 1 shared paper, 2026 · strength 0.29
  4. Yang Feng Wu · 1 shared paper, 2026 · strength 0.29
  5. Maximilian Weniger · 1 shared paper, 2026 · strength 0.29
  6. Jan Goesta D’Haese · 1 shared paper, 2026 · strength 0.29
  7. Jens Werner · 1 shared paper, 2026 · strength 0.29
  8. Su Hu · 1 shared paper, 2026 · strength 0.28
  9. Yujia Wang · 1 shared paper, 2026 · strength 0.28
  10. Wei Zhao · 1 shared paper, 2026 · strength 0.28
  11. Rui Fu · 1 shared paper, 2026 · strength 0.28
  12. Y P. Li · 1 shared paper, 2026 · strength 0.28
  13. Khemayanto Hidayat · 1 shared paper, 2026 · strength 0.28
  14. Jie Zhou · 1 shared paper, 2026 · strength 0.28
  15. Wei Li · 1 shared paper, 2026 · strength 0.23
  16. Chunyi Hao · 1 shared paper, 2026 · strength 0.23
  17. Haitao Zhang · 1 shared paper, 2026 · strength 0.23
  18. Guang Tan · 1 shared paper, 2026 · strength 0.23
  19. Ke Cheng · 1 shared paper, 2026 · strength 0.23
  20. Liwei Wang · 1 shared paper, 2026 · strength 0.23
  21. Huanji Xu · 1 shared paper, 2026 · strength 0.23
  22. Dan Cao · 1 shared paper, 2026 · strength 0.23
  23. Jianhui Wu · 1 shared paper, 2026 · strength 0.23
  24. Jiujie Cui · 1 shared paper, 2026 · strength 0.23
  25. Kuirong Jiang · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.